Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2023 01:00 ET | Source: ObsEva SA

ObsEva Files half Year 2023 Financial Statements

ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...
July 13, 2023 01:00 ET | Source: ObsEva SA

ObsEva Recovers Full Worldwide Rights on Nolasiban

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
June 30, 2023 01:00 ET | Source: ObsEva SA

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
June 08, 2023 01:00 ET | Source: ObsEva SA

Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
May 02, 2023 01:00 ET | Source: ObsEva SA

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...
April 28, 2023 12:00 ET | Source: ObsEva SA

ObsEva Annual Report 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
April 20, 2023 07:00 ET | Source: ObsEva SA

ObsEva Announces Change of Central Securities Depositary

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
April 20, 2023 01:00 ET | Source: ObsEva SA

ObsEva Announces Change of Central Securities Depositary

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
March 31, 2023 16:01 ET | Source: ObsEva SA

ObsEva Files Year End 2022 Financial Statements

ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market:...
March 15, 2023 07:00 ET | Source: ObsEva SA

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...